
FDA approves Etcamah for breast cancer with specific mutation
The story in brief
The US FDA approved AstraZeneca’s Etcamah for breast cancer patients with a specific mutation, based on the SERENA-6 trial showing a 56% reduction in disease progression or death risk. The drug, a next-gen SERD, is taken once daily and requires an FDA-approved test to confirm eligibility.